Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Accumulated Expenses (2016 - 2024)

Historic Accumulated Expenses for United Therapeutics (UTHR) over the last 16 years, with Q4 2024 value amounting to $338.5 million.

  • United Therapeutics' Accumulated Expenses rose 1576.61% to $338.5 million in Q4 2024 from the same period last year, while for Dec 2024 it was $338.5 million, marking a year-over-year increase of 1576.61%. This contributed to the annual value of $338.5 million for FY2024, which is 1576.61% up from last year.
  • Per United Therapeutics' latest filing, its Accumulated Expenses stood at $338.5 million for Q4 2024, which was up 1576.61% from $292.4 million recorded in Q4 2023.
  • In the past 5 years, United Therapeutics' Accumulated Expenses registered a high of $338.5 million during Q4 2024, and its lowest value of $170.8 million during Q4 2021.
  • Its 5-year average for Accumulated Expenses is $242.1 million, with a median of $225.8 million in 2022.
  • Per our database at Business Quant, United Therapeutics' Accumulated Expenses crashed by 661.56% in 2021 and then soared by 3220.14% in 2022.
  • Quarter analysis of 5 years shows United Therapeutics' Accumulated Expenses stood at $182.9 million in 2020, then decreased by 6.62% to $170.8 million in 2021, then soared by 32.2% to $225.8 million in 2022, then grew by 29.5% to $292.4 million in 2023, then increased by 15.77% to $338.5 million in 2024.
  • Its Accumulated Expenses was $338.5 million in Q4 2024, compared to $292.4 million in Q4 2023 and $225.8 million in Q4 2022.